5-Fluoro-2-(trifluoromethyl)benzaldehyde, 97.0%, 5g

2,3,6-Trifluorobenzylamine, 97.0%, 10g

5-(4-tert-butylphenyl)-1H-pyrazole-4-carboxylic acid, 95.0%, 1g

2-Bromo-5-(cyclopropylsulfamoyl)benzoic acid, 97%, 100mg

N-methoxy-N,3,5-trimethylbenzamide, 95.0%, 10g

(S)-2-((tert-Butoxycarbonyl)amino)-3-(pyridin-2-yl)propanoic acid, 95.0%, 5g

4-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)isoquinoline, 95%, 250mg

TMS-HT Kit (=HMDS and TMCS in Anhydrous Pyridine) 1 mL * 8 / Reaction vial, capacity 2 mL * 8 [Trimethylsilylating Reagent, for OH compounds]1kit

Methyl 4-({[(tert-Butoxy)carbonyl]amino}methyl)piperidine-4-carboxylate, 95%, 5g

(8R,9S,13S,14S,17S)-3-Hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl acetate, 95.0%, 100mg

N-(tert-Butoxycarbonyl)-3-fluoro-L-phenylalanine>98.0%(HPLC)(T)1g

7-BROMO-2,2-DIMETHYL-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE, 97.0%, 250mg

Ethyl Ricinoleate>80.0%(GC)25mL